We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,481 hedge funds and large institutions have $102B invested in Bristol-Myers Squibb in 2023 Q2 according to their latest regulatory filings, with 126 funds opening new positions, 947 increasing their positions, 1,065 reducing their positions, and 163 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $1.43B | Put options by funds: $995M

0.44% less ownership

Funds ownership: 76.44%76% (-0.44%)

2% less funds holding

Funds holding: 2,5412,481 (-60)

8% less capital invested

Capital invested by funds: $111B → $102B (-$8.64B)

11% less repeat investments, than reductions

Existing positions increased: 947 | Existing positions reduced: 1,065

23% less first-time investments, than exits

New positions opened: 126 | Existing positions closed: 163

35% less funds holding in top 10

Funds holding in top 10: 6844 (-24)

Holders
2,481
Holders Change
-60
Holders Change %
-2.36%
% of All Funds
38.95%
Holding in Top 10
44
Holding in Top 10 Change
-24
Holding in Top 10 Change %
-35.29%
% of All Funds
0.69%
New
126
Increased
947
Reduced
1,065
Closed
163
Calls
$1.43B
Puts
$995M
Net Calls
+$431M
Net Calls Change
-$137M
Name Holding Trade Value Shares
Change
Change in
Stake
SC
901
SouthState Corp
Florida
$2.31M -$163K -2,425 -6%
BFIM
902
Beese Fulmer Investment Management
Ohio
$2.31M -$239K -3,571 -9%
FWTB
903
First Western Trust Bank
Colorado
$2.31M -$191K -2,848 -7%
CA
904
Corrado Advisors
New Jersey
$2.3M -$12.4K -185 -0.5%
RWM
905
RKL Wealth Management
Pennsylvania
$2.3M +$9.32K +139 +0.4%
GFA
906
Gifford Fong Associates
California
$2.3M
GIM
907
Guardian Investment Management
California
$2.29M -$622K -9,278 -21%
CWM
908
Concentric Wealth Management
California
$2.29M +$82.9K +1,237 +4%
CWM
909
C2C Wealth Management
Arizona
$2.28M +$19.4K +290 +0.8%
MME
910
Meag Munich Ergo
Germany
$2.28M +$1.41M +21,065 +145%
LS
911
Leelyn Smith
Illinois
$2.28M -$97K -1,447 -4%
SFA
912
Sequoia Financial Advisors
Ohio
$2.26M +$125K +1,870 +6%
HSA
913
HBK Sorce Advisory
Pennsylvania
$2.24M -$233K -3,482 -9%
P
914
Pitcairn
Pennsylvania
$2.24M -$1.03M -15,361 -30%
AFA
915
Abacus FCF Advisors
Florida
$2.24M +$340K +5,076 +17%
SAM
916
Smithbridge Asset Management
Pennsylvania
$2.24M -$26.9K -401 -1%
IHL
917
Investment House LLC
California
$2.23M -$1.68M -25,000 -42%
SLI
918
Sumitomo Life Insurance
Japan
$2.23M -$226K -3,363 -9%
CCMINC
919
Cardinal Capital Management Inc (North Carolina)
North Carolina
$2.21M +$2.31M +34,493 New
VFA
920
Valeo Financial Advisors
Indiana
$2.19M -$31.1K -464 -0.9%
OSNBOA
921
Old Second National Bank of Aurora
Illinois
$2.18M -$50.8K -758 -2%
PIMJS
922
PKO Investment Management Joint-Stock
Poland
$2.17M +$738K +11,000 +48%
BBA
923
BLB&B Advisors
Pennsylvania
$2.17M -$76.2K -1,137 -3%
PT
924
Plimoth Trust
Massachusetts
$2.17M -$70.4K -1,050 -3%
RPWA
925
Regent Peak Wealth Advisors
Georgia
$2.16M -$55.3K -825 -2%

BMY Hedge Fund Activity: Q2 2023 in Review

2,481 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2023, worth a combined $102B — down 7.8% from $111B a quarter earlier.

Sellers outnumbered buyers: 163 funds closed out of BMY and 126 opened new positions — a net loss of 37 holders — while 1,065 trimmed existing stakes and 947 added.

The largest buyer was Capital International Investors, adding an estimated $528M. The largest seller was Bank of America, cutting an estimated $634M.

  • 2,481 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2023, down from 2,541 in Q1 2023.
  • Funds reported $102B of Bristol-Myers Squibb stock for Q2 2023, down 7.8% quarter-over-quarter.
  • 126 funds opened new Bristol-Myers Squibb positions in Q2 2023 and 163 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2023 was Capital International Investors, an estimated $528M added.
  • The largest Bristol-Myers Squibb seller in Q2 2023 was Bank of America, an estimated $634M sold.

Based on aggregated 13F filings for Q2 2023.